New hope for black caribbean women with aggressive breast cancer: could a different chemo drug work better?

NCT ID NCT07528768

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two chemotherapy drugs—gemcitabine and paclitaxel—in Black Caribbean women with metastatic triple-negative breast cancer. The goal is to see if gemcitabine, usually used later, works better as a first treatment. 750 women from Jamaica, Trinidad, and Barbados will take part, with regular check-ups and scans to track results.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • St. James Medical Complex

    Port of Spain, Saint James, Trinidad and Tobago

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Queen Elizabeth Hospital

    Bridgetown, Saint Michael, Barbados

    Contact Email: •••••@•••••

  • The University of the West Indies, Mona

    Mona, Kingston, Jamaica

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••